{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-179401","form_type":"8-K","ticker":"NTLA","cik":"0001652130","company_name":"Intellia Therapeutics, Inc.","filed_at":"2026-04-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.669586+00:00","generated_at":"2026-05-15T03:52:23.962758+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Intellia announces positive Phase 3 HAELO results: 87% attack reduction, 62% attack-free; starts BLA for lonvo-z","bullets":["Single dose of lonvo-z reduced HAE attacks by 87% vs placebo (mean monthly rate 0.26 vs 2.10, p<0.0001) over 6 months.","62% of lonvo-z patients were entirely attack-free and therapy-free vs 11% on placebo (p<0.0001); all key secondary endpoints met.","No serious adverse events; all TEAEs mild/moderate; most common: infusion-related reactions, headache, fatigue.","Rolling BLA submission to FDA initiated; potential U.S. launch in first half of 2027 if approved.","Median follow-up 7.5 months; all lonvo-z patients remained long-term prophylaxis-free as of Feb 10, 2026 cutoff."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-179401","json":"https://secwatch.observer/filing/0001193125-26-179401.json","markdown":"https://secwatch.observer/filing/0001193125-26-179401.md","text":"https://secwatch.observer/filing/0001193125-26-179401.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526179401/0001193125-26-179401-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526179401/d138980d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T03:52:23.962758+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}